3 Stocks That May Be Trading Below Their Estimated Fair Value

In This Article:

As global markets navigate heightened geopolitical tensions and unexpected economic shifts, investors are closely monitoring the impact on various sectors. Despite these challenges, opportunities may arise in stocks that are trading below their estimated fair value, presenting potential for growth when market conditions stabilize. Identifying such stocks involves assessing their fundamentals and market position relative to current events, making them appealing options for those seeking value in a volatile environment.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

goeasy (TSX:GSY)

CA$182.97

CA$361.57

49.4%

Associated Banc-Corp (NYSE:ASB)

US$21.02

US$41.74

49.6%

Western Alliance Bancorporation (NYSE:WAL)

US$84.41

US$168.65

50%

Zhejiang Great Shengda PackagingLtd (SHSE:603687)

CN¥7.11

CN¥14.16

49.8%

JD Sports Fashion (LSE:JD.)

£1.3865

£2.75

49.7%

Symbotic (NasdaqGM:SYM)

US$23.84

US$47.66

50%

Sejin Heavy Industries (KOSE:A075580)

?7490.00

?14930.31

49.8%

Super Group (JSE:SPG)

ZAR23.28

ZAR46.16

49.6%

Feytech Holdings Berhad (KLSE:FEYTECH)

MYR0.87

MYR1.73

49.7%

MTU Aero Engines (XTRA:MTX)

€284.20

€567.26

49.9%

Click here to see the full list of 951 stocks from our Undervalued Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

Daiichi Sankyo Company

Overview: Daiichi Sankyo Company, Limited is a pharmaceutical manufacturer and seller operating in Japan, North America, Europe, and internationally with a market cap of ¥9.23 trillion.

Operations: The company generates revenue of ¥1.69 trillion from its pharmaceutical operations across various regions.

Estimated Discount To Fair Value: 24.6%

Daiichi Sankyo appears undervalued based on cash flow analysis, trading at ¥4,897, below its estimated fair value of ¥6,492.1. Recent developments include a completed share buyback program worth approximately ¥120 billion and significant advancements in their oncology pipeline with ENHERTU receiving Priority Review in the US. The company's revenue is projected to grow by 12.9% annually, outpacing the Japanese market average of 4.2%, highlighting potential for future growth.

TSE:4568 Discounted Cash Flow as at Oct 2024
TSE:4568 Discounted Cash Flow as at Oct 2024

Taiwan Semiconductor Manufacturing

Overview: Taiwan Semiconductor Manufacturing Company Limited, along with its subsidiaries, is engaged in the manufacturing, packaging, testing, and selling of integrated circuits and semiconductor devices globally; it has a market cap of NT$25.34 trillion.